The Clinical Efficacy of Balloon-Assisted Maturation of Autogenous Arteriovenous Fistulae.

BACKGROUND: Delayed maturation of arteriovenous fistulae (AVF) among patients who require hemodialysis (HD) can lead to catheter sepsis with its resultant morbidity and mortality. Some have proposed that sequential balloon-assisted maturation (BAM) may accelerate the maturation times of these accesses. On the other hand, serial balloon angioplasty of normal vein may result in stenosis and delay maturation. Although the safety of BAM has been shown, direct comparison to nonmatured AVF has not been explored. Therefore, we conducted a retrospective analysis of our prospectively maintained vascular access database to compare the duration of period to AVF maturation between patients who received BAM and those who were not referred for BAM at our institution. METHODS: Prospectively collected data over a 3-year period in 194 patients who underwent AVF creation at our institution were retrospectively analyzed. The duration to maturation of the AVF was determined by comparing the period between the creation of the fistula and the first successful cannulation of the fistula. Only patients on HD were included. Patients who underwent BAM or placement of AVF at an outside institution were excluded. Follow-up consisted reviewing of postoperative AVF duplex for patency, hospital and clinic databases, HD center databases, and telephone interviews. RESULTS: Of the 194 patients who had AVF placement, 172 patients were on HD within 2 weeks of AVF placement, whereas 22 patients had AVF placed in anticipation of the need for HD. Of the 172 patients on HD within 2 weeks, 54 patients had BAM performed at our institution and 4 patients had BAM at an outside institution, whereas 114 patients were not referred for BAM. Thirty-three of these 114 patients were age and gender matched to compare to the patients who underwent BAM at our institution. At the time of this analysis, of the 54 patients who had BAM, 30 had functional AVF (19 men, 11 women; mean age, 62 years; range, 26-86 [standard deviation, SD ± 18] years). In the BAM group of functioning AVF, n = 30, the total number of procedures was 125 (range, 1-8, average 4). The overall average duration to maturation of the AVF was 119 days (SD ± 84 days) and 146 days (SD ± 157 days) P = 0.73, for BAM and non-BAM, respectively. CONCLUSIONS: These preliminary data suggest the role of BAM did not decrease maturation times of AVF and that BAM warrants further scrutiny before further adoption.

To BAM or not to BAM?: A closer look at balloon-assisted maturation.

BACKGROUND: Balloon assisted maturation (BAM) is a recent, innovative, yet controversial method for developing autogenous arterio-venous fistulae (AVF), with little supportive data. Few retrospective studies have addressed the efficacy of BAM and cofactors affecting successful maturation. We conducted a retrospective analysis of our vascular access database to compare possible factors associated with a successful BAM, as determined by increase in volume flow of the fistulae. METHODS: Between 2009 and 2010, data was prospectively collected on patients undergoing BAM of their AVF under ultrasound guidance at our institution. 30 of these patients, consisting of 143 BAMs, were retrospectively analyzed. Data collection included: past medical history, age, number of BAM procedures preformed, volume flow measurement (VFM) in mid-fistulae, size of balloon used, and presence of post procedural wall hematoma. VFM was determined with duplex within one month prior to and subsequent to each BAM performed. RESULTS: Of the 30 patients, consisting of 143 BAMs, the average age was 69 years old + 15 (range 38-92) with 20 males and 10 females. The most common risk factors were hypertension (n = 27) and diabetes mellitus (n = 16). The average BAM per patient was 4.8 (range 1-7). Of the 143 BAM procedures, 4 were excluded due to absence of preoperative or postoperative duplex. In 139 BAMs, 74 developed a post procedural hematoma as observed on duplex, and 76 showed an increase in VFM. In all BAMs analyzed, there was no correlation observed between the presence of a hematoma and increase in VFM (P = 0.87). Hematomas occurred most frequently during the second BAM procedure, with 24.3% of all hematomas observed. In 139 BAMs, 8 different balloon sizes were used, 3 mm-10 mm, with the 7mm balloon being the most frequently used (n = 34). No significant difference was noted between increase in VFM in 3 mm to 7 mm balloons. A 8 mm balloon was used in 31 BAMs with 22 developing hematomas. Of the 8mm balloon group, a statistical difference was noted between percent increase in VFM with presence of a hematoma and percent increase in VFM without presence of a hematoma (P = 0.027). CONCLUSIONS: These preliminary data, suggest that a more aggressive approach to BAM, with use of larger balloons to create hematoma formation and minimizing excessive dilatation procedures, may have a significant impact on performing a successful maturation in respects to increase in VFM.

Clinical experience with office-based duplex-guided balloon-assisted maturation of arteriovenous fistulas for hemodialysis.

BACKGROUND: To examine the effect of office-based duplex-guided balloon-assisted maturation (DG-BAM) on arteriovenous fistula (AVF), we retrospectively analyzed our experience. METHODS: Over the past 10 months, we performed 185 DG-BAMs (range, 1-8 procedures; mean, 3.7) in 45 patients (29 male, 16 female; mean age, 68.2 ± 12.8 years) with 31 radial-cephalic, 7 brachial-cephalic, and 7 brachial-basilic AVFs. Balloon sizes (3-10 mm) were chosen based on duplex measurements (1-2 mm larger than minimal vein diameter). Forearm AVFs were dilated to 8 mm, and arm AVFs were dilated to 10 mm. RESULTS: All cases but one (99.5%) were successfully dilated. This exception was a large AVF rupture that required surgical repair. AVFs failed to mature in seven of the remaining 44 patients (16%) despite DG-BAM because of proximal vein stenoses (PVS). Four patients had cephalic arch stenoses, and three had proximal subclavian vein stenoses. Arm AVFs were more commonly associated with PVS (6 of 14 patients, 43%) as compared with the ones placed in the forearm (1 of 30 patients, 3.3%), with a P value of 0.0024. All these seven AVFs subsequently matured after successful balloon angioplasty of the venous outflow. CONCLUSIONS: These data suggest that office-based DG-BAM of AVFs is feasible, safe, and averts nephrotoxic contrast and radiation. PVS appear to be the most common cause of failure for AVFs subjected to BAM. Because arm AVFs are at increased risk of PVS, we suggest that a careful duplex evaluation of the outflow be performed in these cases and in all AVFs that fail to mature.